摘要
目的:研究甲状腺肿瘤患者褪黑素(MLT)与褪黑素受体(MR)表达的改变及意义。方法:取甲状腺肿瘤(腺瘤及腺癌)组织及腺瘤旁1cm正常组织匀浆及自身外周血,用ELISA方法检测MLT浓度改变,以免疫组化SP法检测MR蛋白改变,RT-PCR半定量分析MR亚型mRNA表达的改变。结果:ELISA方法显示,甲状腺肿瘤组织匀浆上清MLT浓度较自身外周血明显增高;甲状腺腺癌组高于腺瘤组和瘤旁组织组;甲状腺腺瘤组高于瘤旁组织组,但无统计学差异;各组外周血MLT浓度无统计学差异。免疫组化方法显示,成人甲状腺腺癌细胞膜、细胞质和细胞核中MT2亚型蛋白均呈棕褐色强阳性染色(+++),较腺瘤及瘤旁正常甲状腺组织染色强度明显增加;mt1受体蛋白亚型表达无差异。RT-PCR结果显示,人甲状腺腺瘤、腺癌及瘤旁正常甲状腺组织均有mt1、MT2受体表达,甲状腺腺瘤组mt1、MT2受体亚型表达量与正常甲状腺组织无差异,甲状腺腺癌组MT2受体亚型表达量较正常甲状腺组织明显增加,mt1受体亚型表达量无差异。结论:成人甲状腺肿瘤组织中MLT浓聚,存在mt1、MT2受体亚型,其中腺癌的细胞膜、细胞质、细胞核内MT2呈高表达。提示MLT与甲状腺肿瘤有一定关联,可能主要通过MT2受体发挥抗甲状腺腺癌作用。
Objective:To investigate the different expression of melatonin and melatonin receptor in patients with thyroid neoplasm. Methods:Thyroid neoplasms( adenocarcinoma and adenoma) and normal thyroid tissue( 1 cm away from adenoma)and the serum were tested the concentration of melatonin by ELISA. The thyroid neoplasm tissues and normal thyroid tissues were detected the melatonin receptor subtypes with immunohistochemistry and RT-PCR. Results: Thyroid neoplasm homogenate had a higher concentration of MLT than their serum. The group adenocarcinoma was higher than group adenoma and group of normal thyroid tissue, the group adeno was higher than the group of normal thyroid tissue, but without significance in. Strong MT2 receptor subtype expression that had brown granules deposited in the membrane, cytosol and nuclear of the thyroid cell was observed in group adenocarcinoma than group adenoma and normal thyroid. Weak mt1 receptor subtype expression was observed in all groups, mt1 and MT2 melatonin receptor subtype positive strap expressed in all groups. MT2 in adenocarcinoma had a higher quantity than normal thyroid tissue. The expression of mt1 in adenocarcinoma and mt1, MT2subtype in adenoma had no significance than normal thyroid tissue. Conclusion:There exists mt1 and MT2 subtype in human thyroid neoplasm tissue, MT2 subtype has association with the occurrence of human adenocarcinoma.
出处
《临床肿瘤学杂志》
CAS
2007年第11期843-846,849,共5页
Chinese Clinical Oncology
关键词
褪黑素
褪黑素受体
甲状腺肿瘤
Melatonin
Melatonin receptor
Thyroid neoplasm